A COMPARATIVE STUDY OF DIABETIC MACULOPATHY AMONG NON PROLIFERATIVE AND PROLIFERATIVE DIABETIC RETINOPATHY PATIENTS

Main Article Content

Dr. Subbulakshmi. S
Dr. Arun Vaidhya. T
Dr. Hamsa. V.S

Keywords

Diabetic Maculopathy, Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy

Abstract

Background: Diabetic Retinopathy is due to the microangiopathy changes in the retinal precapillary arterioles, capillaries and venules. Diabetic Maculopathy is the leading cause of blindness in Diabetic Retinopathy. Retinal ischemia and edema are the two major intraretinal components of Diabetic Maculopathy. Visual loss is caused by the breakdown of blood retinal barrier, which leads to increase in the extracellular fluid within the retina, resulting in distortion of the retinal architecture. However, Diabetic Retinopathy has an unpredictable evolution and control of this disease is challenging. Hence, with timely detection and treatment, proper follow up and Diabetes Mellitus care, visual loss can be prevented.


This study is done to compare Diabetic Maculopathy among Non-Proliferative and Proliferative Diabetic Retinopathy patients. Thus, leading to early treatment and prevention of blindness due to Diabetic Maculopathy.


Objective: Comparison of Diabetic Maculopathy among Non-Proliferative and Proliferative Diabetic Retinopathy in Type 2 diabetic patients.


Methodology: Non-Proliferative and Proliferative Diabetic Retinopathy patients were prospectively enrolled. All the participants in the study were interviewed using a wellstructured proforma. Patient’s details including age, sex, type and duration of diabetes, treatment history were recorded. Complete Ocular examination was done including Best corrected visual acuity (BCVA), Anterior segment examination using Slit lamp Retinoscopy, Intraocular pressure measurement using Applanation Tonometer, Amsler Grid, Posterior segment examination includes dilated fundus examination with indirect Ophthalmoscope and Slit lamp biomicroscopy using +90D. Fundus Photography will be taken for documentation using canon fundus camera. Statistical analysis was performed using SPSS software.


Results: This prospective study was conducted in the Department of Ophthalmology at Vinayaka Missions Medical College, Karaikal. On approval by ethical committee, 100 Diabetic Retinopathy patients were recruited after obtaining informed consent. According to ETDRS Classification patients were recruited in two groups. 50 patients were in non-proliferative and 50 patients were in proliferative Diabetic Retinopathy group. The maximum number of patients belonged to the age group of 51-60 years ie.34 patients (68%) in NPDR Group and 61-70 years ie.21 patients (42%) in PDR group. Females outnumbered males i.e. 26 patients (52%) in NPDR group and 30 patients (60%) in PDR group. The results of the study showed that 21 patients (68%) in NPDR Group had developed Diabetic Maculopathy when compared to PDR Group ie.10 patients (32%) and which was found to be statistically significant. The results of the study also showed that within NPDR group, severe NPDR patients i.e. 10 patients (47%) developed Diabetic Maculopathy when compared to Mild and Moderate NPDR patients.


Conclusion: The results of the study showed that 21 patients (68%) in NPDR Group had developed Diabetic Maculopathy when compared to PDR Group ie.10 patients (32%). The results of the study also showed that within NPDR group, severe NPDR patients i.e. 10 patients (47%) developed Diabetic Maculopathy when compared to Mild and Moderate NPDR patients. Since, the prevalence of Diabetic Maculopathy is increasing nowadays in both NPDR and PDR patients, it is advisable to undergo fundus examinations periodically at regular intervals to detect the Diabetic Maculopathy at the earliest. Early treatment with photocoagulation can stabilize the visual acuity and prevent further visual loss. So, it is recommended that diabetic patients should have regular retinal examinations through a dilated pupil within 3–5 years of diabetes and follow-up yearly.

Abstract 96 | PDF Downloads 38

References

Raman R, Gupta A, Krishna S, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27) J Diabetes Complications. 2012; 26(2):123–8. doi: 10.1016/j.jdiacomp.2012.02.001. [PubMed] [Cross Ref]
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010; 376(9735):124–36. doi: 10.1016/S0140-6736(09)62124-3. [PubMed] [Cross Ref]
3. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al.Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet GlobHealth. 2013;1(6):e339–49. doi: 10.1016/S2214-109X(13)70113-X. [PubMed] [Cross Ref]
4. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al.Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care.2012;35(3):556–64. doi: 10.2337/dc11-1909. [PMC free article] [PubMed] [Cross Ref]
5. Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003; 5(2):12–21. doi: 10.1016/S1098-3597(03)90015-9. [PubMed] [Cross Ref]
6. Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, et al.The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. J Diabetes Complications. 2014; 28(6):874–9. doi:10.1016/j.jdiacomp.2014.07.001. [PMC free article] [PubMed] [Cross Ref]
7. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al.Prevalence of Diabetic Retinopathy within a national Diabetic Retinopathy screening service. Br J Ophthalmol. 2015; 99(1):64–8. doi: 10.1136/bjophthalmol-2013-304017. [PubMed] [Cross Ref]
8. Pedro RA, Ramon SA, Marc BB, Juan FB, Isabel MM. Prevalence and relationship between Diabetic Retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. Ophthalmic Epidemiol. 2010; 17(4):251–65. doi: 10.3109/09286586.2010.498661. [PubMed] [Cross Ref]
9. Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, et al. Tromso eye study: prevalence and risk factors of diabetic retinopathy. Acta Ophthalmol. 2013; 91(8):716–21. doi: 10.1111/j.1755-3768.2012.02542.x. [PubMed] [Cross Ref]
10. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The north Jutland CountyDiabetic Retinopathy study: population characteristics. Br J Ophthalmol. 2006; 90(11):1404–9. doi: 10.1136/bjo.2006.093393. [PMC free article] [PubMed] [Cross Ref]
11. Dedov I, Maslova O, Suntsov Y, Bolotskaia L, Milenkaia T, Besmertnaia L.Prevalence of Diabetic Retinopathy and cataract in adult patients with type 1 and type2diabetesin Russia. Rev Diabet Stud. 2009;6(2):124–9. doi:9.10.1900/RDS.2009.6.124. [PMC free article] [PubMed] [Cross Ref]
12. Roy MS, Klein R, O’Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of Diabetic Retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004; 122(4):546–51. doi: 10.1001/archopht.122.4.546. [PubMed] [Cross Ref]
12. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al.The prevalence of Diabetic Retinopathy among adults in the United States. Arch Ophthalmol. 2004; 122(4):552–63. doi: 10.1001/archopht.122.4.552. [PubMed] [Cross Ref]
13. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al.Prevalence of Diabetic Retinopathy in the United States, 2005–2008. JAMA. 2010; 304(6):649–56. doi: 10.1001/jama.2010.1111. [PMC free article] [PubMed] [CrossRef]
14. Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, UthraS, Kumaramanic kavel G, et al. Prevalence of Diabetic Retinopathy in India: SankaraNethralaya Diabetic Retinopathy epidemiology and molecular genetics study report 2. Ophthalmology. 2009; 116(2):311–8. doi: 10.1016/j.ophtha.2008.09.010. [PubMed] [Cross Ref]
15. Liu L, Wu X, Liu L, Geng J, Yuan Z, Shan Z, et al. Prevalence of Diabetic Retinopathy in mainland China: a meta-analysis. PLoS One. 2012; 7(9):e45264. doi:10.1371/journal.pone. 0045264. [PMC free article] [PubMed] [Cross Ref]
16. Huang OS, Tay WT, Ong PG, Sabanayagam C, Cheng CY, Tan GS, et al.Prevalence and determinants of undiagnosed Diabetic Retinopathy and visionthreatening retinopathy in a multi-ethnic Asian cohort: the Singapore Epidemiology of Eye Diseases (SEED) study. Br J Ophthalmol. 2015. [PubMed]
17. Zheng Y, Lamoureux EL, Lavanya R, Wu R, Ikram MK, Wang JJ, et al. Prevalence and risk factors of Diabetic Retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology. 2012; 119(10):2119–9.24. doi: 10.1016/j.ophtha.2012.04.027. [PubMed] [Cross Ref]
18. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of Diabetic Retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46(7):2328–33. doi: 10.1167/iovs.05-0019. [PubMed] [Cross Ref]
19. Al Ghamdi AH, Rabiu M, Hajar S, Yorston D, Kuper H, Polack S. Rapid assessment of avoidable blindness and Diabetic Retinopathy in Taif, Saudi Arabia. Br J Ophthalmol. 2012; 96(9):1168–72. doi: 10.1136/bjophthalmol-2012-301874. [PubMed] [Cross Ref]
20. Papakonstantinou E, Tsinopoulos I, Dimitrakos S, Dehghan MH, Katibeh M,Ahmadieh H, et al. Prevalence and risk factors for Diabetic Retinopathy in the 40 to80 year-old population in Yazd, Iran: the Yazd Eye Study. J Diabetes. 2015; 7(1):139–41. doi: 10.1111/1753-0407.12205. [PubMed] [Cross Ref]
21. Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of Diabetic Retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009; 116(3):461–7.doi:10.1016/j.ophtha .2008.10.003. [PubMed] [Cross Ref]
22. Kung K, Chow KM, Hui EM, Leung M, Leung SY, Szeto CC, et al. Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a crosssectional study. BMC Fam Pract. 2014; 15:8. doi: 10.1186/1471-2296-15-8. [PMC free article] [PubMed] [Cross Ref]
23. Tong L, Vernon SA, Kiel W, Sung V, Orr GM. Association of macular involvement withproliferative retinopathy in type 2 diabetes. Diabet Med. 2001; 18(5):388–94. doi:10.1046/j.1464- 5491.2001.00483.x. [PubMed] [Cross Ref